EUVIMEDEUVIMED entdecken
Open Access

Clinical utility of liver fat quantification for determining cardiovascular disease risk among patients with type 2 diabetes

Selena Z Kuo, Sandra Cepin, Jaclyn Bergstrom, Harris Siddiqi, Jinho Jung iD, Scarlett Lopez, Daniel Q Huang iD, Pam Taub, Maral Amangurbanova, Rohit Loomba iD

Alimentary Pharmacology & Therapeutics · 2023

DOI: 10.1111/apt.17637 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2023. Verfasst von Selena Z Kuo und 9 weiteren Autor:innen. Beteiligte Einrichtung: NAFLD Research Center, Division of Gastroenterology, University of California at San Diego, La Jolla, California, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Cardiovascular Diseases, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NIDDK NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are independent risk factors for cardiovascular disease (CVD).

Aims

To examine the clinical utility of liver fat quantification for determining CVD risk among a well‐phenotyped cohort of patients with T2DM.

Methods

This was a cross‐sectional analysis of a prospective cohort of adults aged ≥50 with T2DM. Liver fat was quantified with magnetic resonance imaging proton‐density‐fat‐fraction (MRI‐PDFF), an advanced imaging‐based biomarker. Patients were stratified into a higher liver fat group (MRI‐PDFF ≥ 14.6%), and a lower liver fat group (MRI‐PDFF < 14.6%). The co‐primary outcomes were CVD risk determined by Framingham and Atherosclerotic Cardiovascular Disease (ASCVD) risk scores. High CVD risk was defined by risk scores ≥20%.

Results

Of the 391 adults (66% female) in this study, the mean (±SD) age was 64 (±8) years and BMI 30.8 (±5.2) kg/m 2 , respectively. In multivariable analysis, adjusted for age, gender, race, and BMI, patients in the higher liver fat group had higher CVD risk [OR = 4.04 (95% CI: 2.07–7.88, p < 0.0001)] and ASCVD risk score [OR = 2.85 (95% CI: 1.19–6.83, p = 0.018)], respectively.

Conclusion

Higher liver fat content increases CVD risk independently of age, gender, ethnicity and BMI. These findings raise the question whether liver fat quantification should be incorporated into risk calculators to further stratify those with higher CVD risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Cardiovascular DiseasesNon-alcoholic Fatty Liver DiseaseAdultHumansFemaleMaleCross-Sectional StudiesProspective StudiesLiverMagnetic Resonance Imaging

Stichwörter der Autor:innen

cardiovascular disease riskdiabetesnon-invasive imagingnonalcoholic fatty liver disease

Autor:innen und Institutionen

  • NAFLD Research Center, Division of Gastroenterology, University of California at San Diego, La Jolla, California, USA.
  • Division of Gastroenterology, University of California at San Diego, La Jolla, California, USA.
  • Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore, Singapore.
  • Division of Cardiovascular Medicine, Department of Medicine, University of California at San Diego, La Jolla, California, USA.

ORCID-Profile: Jinho Jung, Daniel Q Huang, Rohit Loomba

Förderung

  • NCATS NIH HHS
  • NIDDK NIH HHS
  • NHLBI NIH HHS
  • NIAAA NIH HHS
  • National Center for Advancing Translational Sciences
  • National Heart, Lung, and Blood Institute
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Institute on Alcohol Abuse and Alcoholism

Zitieren

APA

Kuo, S. Z., Cepin, S., Bergstrom, J., Siddiqi, H., Jung, J., Lopez, S., Huang, D. Q., Taub, P., Amangurbanova, M., & Loomba, R. (2023). Clinical utility of liver fat quantification for determining cardiovascular disease risk among patients with type 2 diabetes. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17637

Vancouver

Kuo SZ, Cepin S, Bergstrom J, Siddiqi H, Jung J, Lopez S, et al. Clinical utility of liver fat quantification for determining cardiovascular disease risk among patients with type 2 diabetes. Alimentary Pharmacology & Therapeutics. 2023. doi:10.1111/apt.17637

BibTeX
@article{Kuo2023,
  author = {Kuo, Selena Z and Cepin, Sandra and Bergstrom, Jaclyn and Siddiqi, Harris and Jung, Jinho and Lopez, Scarlett and Huang, Daniel Q and Taub, Pam and Amangurbanova, Maral and Loomba, Rohit},
  title = {Clinical utility of liver fat quantification for determining cardiovascular disease risk among patients with type 2 diabetes},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2023},
  doi = {10.1111/apt.17637}
}
Kostenlos starten →